SynthesisGut2003
Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase.
Synthesis in Gut, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Long Term Follow-up of Pegylated-Interferon Alpha-2b and Lamivudine Combination Therapy in Patients With Chronic HBV Infection
An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide Analogue Therapy
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 172 citations in OpenAlex.
- Pooled it
- SASLT practice guidelines for the management of hepatitis B virus.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationGuideline
- Trial
- Correlation of quantitative assay of HBsAg and HBV DNA levels during chronic HBV treatment.Digestive diseases and sciences · 2008Trial
- Trial
- Recommendations for treatment of viral hepatitis B in 2026 by the Polish Group of Experts for HBV.Clinical and experimental hepatology · 2026Review
- Lack of association between early on-treatment HBeAg seroclearance and development of hepatocellular carcinoma or decompensated cirrhosis.JHEP reports : innovation in hepatology · 2024Article
- Follow-Up of 108 Patients with Chronic Hepatitis B Virus Infection Treated with Polyethylene Glycol-Conjugated Derivatives of Interferon-Alpha and Monitoring of Off-Treatment Virological Relapse.Medical science monitor : international medical journal of experimental and clinical research · 2022Article
- Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B.Clinical and molecular hepatology · 2016Article
- Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B.BMC gastroenterology · 2016Article
- Future therapy for hepatitis B virus infection.Clinical journal of gastroenterology · 2015Review
- Current and future directions for treating hepatitis B virus infection.World journal of hepatology · 2015Review
- Article
- High risk of hepatitis B virus reactivation in nucleos(t)ide analogue-induced hepatitis B e antigen seroconverters older than 40 years.Digestive diseases and sciences · 2014Article
- Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.World journal of gastroenterology · 2014Review
- When to stop nucleos(t)ide analogues treatment for chronic hepatitis B? Durability of antiviral response.World journal of gastroenterology · 2014Review
- Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments.World journal of gastroenterology · 2014Review
- The role of HBsAg levels in the current management of chronic HBV infection.Annals of gastroenterology · 2014Review
- Article
- Immunoregulation of hepatitis B virus infection--rationale and clinical application.Nagoya journal of medical science · 2012Review
Corrections and comments
- Commented on by
Authors and funding
11 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsInterferon (IFN) induced hepatitis B e antigen (HBeAg) seroconversion is durable in 80-90% of chronic hepatitis B patients. Preliminary reports on the durability of HBeAg seroconversion following lamivudine are contradictory. We investigated the durability of response following IFN, lamivudine, or IFN-lamivudine combination therapy in a meta-analysis of individual patient data. PATIENTS AND
methodsTwenty four centres included 130 patients in total with an HBeAg seroconversion (HBeAg negative, antibodies to hepatitis B e antigen positive) at the end of antiviral therapy: 59 with lamivudine, 49 with interferon, and 22 with combination therapy. Relapse was defined as confirmed reappearance of HBeAg.
resultsThe three year cumulative HBeAg relapse rate by the Kaplan-Meier method was 54% for lamivudine, 32% for IFN, and 23% for combination therapy (p=0.01). Cox regression analysis identified pretreatment hepatitis B virus (HBV) DNA, alanine aminotransferase (ALT), sex, and therapy as independent predictive factors of post-treatment relapse; Asian race, previous therapy, centre, and type of study were not predictive of relapse. The relative HBeAg relapse risk of lamivudine compared with IFN therapy was 4.6 and that of combination therapy to IFN therapy 0.7 (p(overall)=0.01).
conclusionsThe durability of HBeAg seroconversion following lamivudine treatment was significantly lower than that following IFN or IFN-lamivudine combination therapy. The risk of relapse after HBeAg seroconversion was also related to pretreatment levels of serum ALT and HBV DNA, but independent of Asian race.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.